{"name":"ZS Pharma, Inc.","slug":"zs-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":45618000,"netIncome":-64354000,"cash":47402000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Placebo ( subacute phase)","genericName":"Placebo ( subacute phase)","slug":"placebo-subacute-phase","indication":"Other","status":"phase_3"},{"name":"Placebo (acute phase)","genericName":"Placebo (acute phase)","slug":"placebo-acute-phase","indication":"Other","status":"phase_3"},{"name":"Silicified microcrystalline cellulose","genericName":"Silicified microcrystalline cellulose","slug":"silicified-microcrystalline-cellulose","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Placebo ( subacute phase)","genericName":"Placebo ( subacute phase)","slug":"placebo-subacute-phase","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo (acute phase)","genericName":"Placebo (acute phase)","slug":"placebo-acute-phase","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Silicified microcrystalline cellulose","genericName":"Silicified microcrystalline cellulose","slug":"silicified-microcrystalline-cellulose","phase":"marketed","mechanism":"Silicified microcrystalline cellulose is an inert pharmaceutical excipient that acts as a binder and flow agent in tablet formulations.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPVWx6RTlQTmNfaGFJN3QzQUVzWGhXNnlRSHhEUGlUb0lXY0lQcFBFU3RNb2xPQmt0NEFvQi03OG96clNwUUFvcGUyalp4TmVoUnk0UkFvQVdWQm1SZW1iMmdOMkN3RGt5YmloWXlCX2pTQ0NXZnlRRF9hSXVCZjNyRlAtMS1ZRl84R0JjVVVWYmRjZXEzNVJxc0dWYnNIRk1WVm1KZQ?oc=5","date":"2026-03-16","type":"pipeline","source":"BioWorld News","summary":"Pharma USA: R&D not enough – patients need better DTC access - BioWorld News","headline":"Pharma USA: R&D not enough – patients need better DTC access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPN1QzeHo0RmpFeDNvWGZKdWFiek8tQmZISERlYlp5ZTFMRVo5Y2VoMkd4bEZSXzdtVU1sd0ZsM19kX2hmVnAtQkVTN1RvN3dVYTZtSXUzQUhqQkdYVm1UanNNT2FDamJEOEh6Q2YyRks0MFQ5NXh1WFNvQ05ITmtJQTJad04wc3F2SmFyR1NSeUJucEVlYmdfMGk1SldtNEh3Vk1rYnMyZnRrVm1TU2NubG5LaFJ4SWxLc2lidmstN09jQ0pLcTNYY2VwUEhBZFRFYmxfaG5QME8ya3hYRm84bTFKSVRGTS03NzRVeXMyS016Z19iRl9hQ3RKV003akdITVNKMVJfRkJLTnY1ejBMSk52bw?oc=5","date":"2025-04-10","type":"trial","source":"PR Newswire","summary":"Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Out in MASH - PR Newswire","headline":"Rivus Pharmaceuticals Expands Leadership Team and Establishes New San Francisco Bay Area Office Ahead of Phase 2 Read-Ou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQY0lWd1JMY3U1SzhTNWlLSGNMSUFGVDlMTlVpUDdXeXU3QV9HX1VvallwbWl1bUIxZmg2TXBhSkMwOTdWYldKeFpCVW9JcFc5WVZJUFY4Vk8yREk0UDZSbGlqZngwQ1lZSjBVNlI4ZGlncTdkYl8zdmdHa0c3T1p5TmhWYkNiVHE2eHowc3NnNEdobHNEdHc?oc=5","date":"2025-04-10","type":"pipeline","source":"Contract Pharma","summary":"Rivus Pharmaceuticals Expands Leadership Team - Contract Pharma","headline":"Rivus Pharmaceuticals Expands Leadership Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNWjY4MEdaQ0htNlg1RjhHbDB6Z3U5TEVoY25FcVJKU0V0elc0ZVBRQi1qbHZlZEZXbkdDNGYtZEpkNWRXVlFYYTV2WTBfZ3NmanBZVmw5LThUQjQ3RXI2dlk0djZtZloydmtxbVU1QjVnTUpIMFdQbXJtYTJ4aVFsbnIwVWhpbVZJNTRSYjVtVXk3X2czVTZ4R1pLNC1QWTB3ak5Ta3ozMlY4bkNxdFhuSkczbw?oc=5","date":"2017-12-06","type":"pipeline","source":"Bloomberg.com","summary":"Frayed Gasket Delaying Astra's ZS-9 Shows Pharma M&A Perils - Bloomberg.com","headline":"Frayed Gasket Delaying Astra's ZS-9 Shows Pharma M&A Perils","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQVHUwREdiZ1lCY0RMSFlheS12MEVYamI0ZFVrVGVkNUtyUDJvdVpZVFl5dGJDOXlLUzlITjJFSm10M2NOdjcxdmNWekxzd2Z5VFVKczRYd1Bzbm92ZnAzaldRTU5WNEQ5ekMwQ1N3SlRfcU1SUEdjS1BDWFJZMlVwQzFHRFJET09YMWo0cTZmWjJfQ2ZGclRid1RnTjNIak1RZkNOMllJbmQtYlQ4SkNiZUdoZS1EdDluNnJPeEFn?oc=5","date":"2015-12-17","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca completes acquisition of ZS Pharma - AstraZeneca","headline":"AstraZeneca completes acquisition of ZS Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNM1AtTkNvM3lWRTl0Z2dseDlGbWVGTFlmdGEzaXR0akdLcjQydzFQRk1GX0dKdE05UVBmX1dDa1kyUDY0LWVGeTM2ZWZZelRaZDZlQjFqOGlqTVhZQ0NvUklHNDRtTF8ydVk3NUU3M3EyLUlZanhhMVZzemxqa09hN2VWZUo?oc=5","date":"2015-11-10","type":"pipeline","source":"SEC.gov","summary":"EDGAR Filing Documents for 0000950103-15-008777 - SEC.gov","headline":"EDGAR Filing Documents for 0000950103-15-008777","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPVU9vX2NhZ0htaWZmc1dSbDI3UDJ0WGdDWHdFYWJYclFHWTVid0ItWl9aREhuVG1qT1FTOURXblNnWmlzU3Y0ODJ0OFFPcHI0RFNndGFWaVdzNU1Gb2o4bGtNQ3JfSkx3MlQ0WFI1dGxZamFrb3g3Uk1PVkxDVXozWWJRaTNGR3BiaXZSNlI5UFpmd0RXWDVmY21wYWgtNG1fQkJJ?oc=5","date":"2015-11-09","type":"deal","source":"BioPharma Dive","summary":"AstraZeneca leapfrogs Actelion with $2.7B deal for ZS Pharma - BioPharma Dive","headline":"AstraZeneca leapfrogs Actelion with $2.7B deal for ZS Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOV1U0M3VRUVJhNFo4SE1tVVhrUlhXYUdpc2UwbV9yWWRYN2lyNkVqWnR6MGtHYmJYblNUeUdzbXk0RV9oVVhUSlR0N0taX2NFVkNBUnNhN3VDM0RtV2FIZ2tjUzdwTjk3Mm5kcS0ybGRzVVB3bDN0Z2tNWF9rd1pWUm9sb1lPNzNNVkhVSEE5dEFqXzZ5Wl9MM3JwaHBabGwwN1M2aV82azBjTm8xd2x3ODQxMWdGeXZtWFdkaEJjTjFGSWQ2aGg3NXB2YWV4emhhV1FSSTg1U0RiMGtNZ0g0elJQeG85Z1UtRGJCZnZ2UkxRNUpyck5lUE9nSVF6SnZiTnVuZnhB?oc=5","date":"2015-11-06","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca strengthens Cardiovascular and Metabolic disease portfolio with acquisition of ZS Pharma - AstraZeneca","headline":"AstraZeneca strengthens Cardiovascular and Metabolic disease portfolio with acquisition of ZS Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOWM1TUdWWGVEX0lKc25JYXo5eVNGYkRPdU5sekhtZENENDBySTFDSUh0YUs3dmc3QjVtUE53UDdBeFN2WWNmQkxjMDNVRXVsRjV4S2Y2dnRURk9ZYVg2bDIzRTFFYmh5bG90SExZcDc2N193cF94S3RobDYyZEtWTE9IQ19jM3NKeHctNnppS3AybnBTT2Ntbkg2eldUb0hhOWVpOUZJU2Y?oc=5","date":"2015-11-06","type":"deal","source":"European Pharmaceutical Review","summary":"AstraZeneca to acquire ZS Pharma for $2.7 billion - European Pharmaceutical Review","headline":"AstraZeneca to acquire ZS Pharma for $2.7 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNQVR2Um1wUzhJbXVvbGprTHhoMXlaQmZBT0ZMOWZVMjNWZHQxVGU4SHZ2dzRGQ05iTDN2OEViZ0NkSEUzS3VUbEtYUHowV1E0YkZEUUV6Nk4zaGQxQ2hXbmRhRFFxQnlHcVVmNzVqY29HYVJCRnZGZENyXzRNVlNWcnRLTGJVRmxKVmdQQg?oc=5","date":"2015-11-06","type":"deal","source":"WSJ","summary":"AstraZeneca to Buy ZS Pharma for $2.7 Billion - WSJ","headline":"AstraZeneca to Buy ZS Pharma for $2.7 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPdWViZm9YR2VDakNGdXljN3pjLUhJT2tMNlBPODMxQjlCYjZ6cTVSc05OV2JhQ2tZMzNKT2huZTBtR1Y4MkdCOUpRUWdGX3V1OFdUZzJoc2N6LTJCTkJZYzhhMk1kZFRlY05LYkZzZU04NjQwNGJwMDF2NmxxNFhsQm5oRDg3Z2pZNDhVVW1icGNkVVZLVG80cUNXN1Y1cTQ?oc=5","date":"2015-11-06","type":"deal","source":"The Guardian","summary":"AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma - The Guardian","headline":"AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5rT3IwbGlKYVNsTkVMU2g1dWJYWmdnQktwRHNrWU1qcFUxSmpzYUJnUTJ6MXR3a0pNU2phenNqdkh0b3piQUNXUzZqd3pEemMzd0xsUW9KVkgza1phSUZlOUJxM1RUWFlwbG9XdA?oc=5","date":"2015-11-06","type":"deal","source":"Fortune","summary":"Astrazeneca is Buying ZS Pharma for $2.7 billion - Fortune","headline":"Astrazeneca is Buying ZS Pharma for $2.7 billion","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":45618000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-64354000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":47402000,"cashHistory":[],"totalAssets":116162000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}